Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway